Qurient Co., Ltd.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 15, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,029,389 | Anti-Inflammation Compounds In force · High confidence | In force | High confidence | |
| US 9,655,841 | Topical anti-inflammatory pharmaceutical composition with zileuton cream formulation In force · From the USPTO record | In force | From the USPTO record | |
| US 9,855,243 | Topical anti-inflammatory pharmaceutical composition with zileuton cream formulation In force · From the USPTO record | In force | From the USPTO record | |
| US 10,934,274 | Quinoline derivatives as TAM RTK inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 12,606,561 | SUBSTITUTED PYRAZOLO[1,5-a][1,3,5]TRIAZINES AS CDK INHIBITORS In force · High confidence | In force | High confidence | |
| US 12,162,858 | Quinoline Derivatives as Inhibitors of Axl/Mer RTK and CSF1R In force · High confidence | In force | High confidence | |
| US 12,410,165 | Different Forms of 6-Chloro-2-ethyl-n-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide In force · High confidence | In force | High confidence | |
| US 12,582,598 | A Topical Anti-Inflammatory Pharmaceutical Composition Comprising Zileuton In force · High confidence | In force | High confidence | |
| US 12,698,288 | Compounds Having Cyclin-Dependent Kinase(CDK)-Inhibitory Function In force · High confidence | In force | High confidence | |
| US 12,753,181 | Compounds for Degradation of Cyclin-Dependent Kinase 7(CDK7) In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 2 patents in force now held by others · 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 abandoned · 1 no status recorded